Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald B Appel

Showing results (81-90 of 140) with videos related to

Pageof 14
Sort By:
Kidney International|August 17, 2016
The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseasesMarie C Hogan, Heather N Reich, Peter J Nelson, et al.
The New England Journal of Medicine|November 25, 2005
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritisEllen M Ginzler, Mary Anne Dooley, Cynthia Aranow, et al.
Diabetes Care|April 30, 2003
Analysis of metabolic parameters as predictors of risk in the RENAAL studyGerald B Appel, Jai Radhakrishnan, Morrell M Avram, et al.
The Journal of Clinical Investigation|December 5, 2002
NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated alleleHiroyasu Tsukaguchi, Akulapalli Sudhakar, Tu Cam Le, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 10, 2012
Eculizumab for dense deposit disease and C3 glomerulonephritisAndrew S Bomback, Richard J Smith, Gaetano R Barile, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 26, 2011
Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathyRoberta Camilla, Hitoshi Suzuki, Valentina Daprà, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 20, 2023
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous NephropathySean J Barbour, Fernando C Fervenza, Dilshani Induruwage, et al.
Kidney International|January 10, 2018
C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathyAndrew S Bomback, Dominick Santoriello, Rupali S Avasare, et al.
American Journal of Nephrology|December 20, 2003
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathyW Kline Bolton, Daniel C Cattran, Mark E Williams, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2018
<i>UBD</i> modifies <i>APOL1</i>-induced kidney disease riskJia-Yue Zhang, Minxian Wang, Lei Tian, et al.
Pageof 14

Showing results (81-90 of 140) with videos related to

Sort By:
Pageof 14
Kidney International|August 17, 2016
The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseasesMarie C Hogan, Heather N Reich, Peter J Nelson, et al.
The New England Journal of Medicine|November 25, 2005
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritisEllen M Ginzler, Mary Anne Dooley, Cynthia Aranow, et al.
Diabetes Care|April 30, 2003
Analysis of metabolic parameters as predictors of risk in the RENAAL studyGerald B Appel, Jai Radhakrishnan, Morrell M Avram, et al.
The Journal of Clinical Investigation|December 5, 2002
NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated alleleHiroyasu Tsukaguchi, Akulapalli Sudhakar, Tu Cam Le, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 10, 2012
Eculizumab for dense deposit disease and C3 glomerulonephritisAndrew S Bomback, Richard J Smith, Gaetano R Barile, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 26, 2011
Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathyRoberta Camilla, Hitoshi Suzuki, Valentina Daprà, et al.
Clinical Journal of the American Society of Nephrology : CJASN|July 20, 2023
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous NephropathySean J Barbour, Fernando C Fervenza, Dilshani Induruwage, et al.
Kidney International|January 10, 2018
C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathyAndrew S Bomback, Dominick Santoriello, Rupali S Avasare, et al.
American Journal of Nephrology|December 20, 2003
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathyW Kline Bolton, Daniel C Cattran, Mark E Williams, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2018
<i>UBD</i> modifies <i>APOL1</i>-induced kidney disease riskJia-Yue Zhang, Minxian Wang, Lei Tian, et al.
Pageof 14